Coxsackievirus B3-induced myocarditis: Perforin exacerbates disease, but plays no detectable role in virus clearance

American Journal of Pathology

Volumn 153, Issue 2, 1998, Pages 417-428

  Gebhard, John R ^a,b   Perry, Christopher M ^a   Harkins, Stephanie ^a   Lane, Thomas ^a   Mena, Ignacio ^a   Asensio, Valérie C ^a   Campbell, Iain L ^a   Whitton, J Lindsay ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Pharmadigm Incorporated Salt Lake City   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PERFORIN;

ANIMAL MODEL; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS B3; CYTOKINE PRODUCTION; DISEASE COURSE; IMMUNOPATHOLOGY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VIRUS MYOCARDITIS; VIRUS REPLICATION;

EID: 0031830709     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65585-X     Document Type: Article

References (71)

1. O'Connell JB: The role of myocarditis in end-stage dilated cardiomyopathy. Tex Heart Inst J 1987, 14:268-275
2. Gravanis MB, Sternby NH: Incidence of myocarditis: a 10-year autopsy study from Malmo, Sweden. Arch Pathol Lab Med 1991, 115: 390-392
3. Sole MJ, Liu P: Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J Am Coll Cardiol 1993, 22:99A-105A
4. Goodwin JF: Cardiomyopathies and specific heart muscle diseases: definitions, terminology, classifications and new and old approaches. Postgrad Med J 1992, 68(suppl 1):S3-S6
5. Heck CF, Shumway SJ, Kaye MP: The Registry of the International Society for Heart Transplantation: sixth official report, 1989. J Heart Transplant 1989, 8:271-276
6. Hyypia T, Kallajoki M, Maaronen M, Stanway G, Kandolf R, Auvinen P, Kalimo H: Pathogenetic differences between coxsackie A and B virus infections in newborn mice. Virus Res 1993, 27:71-78.
7. Gelfand HM: The occurrence in nature of the coxsackie and ECHO viruses. Prog Med Virol 1961, 3:193-244
8. Woodruff JF: Viral myocarditis: a review. Am J Pathol 1980, 101:425-484
9. Sutton GC, Harding HB, Trueheart RP, Clark HP: Coxsackie B4 myocarditis in an adult: successful isolation of virus from ventricular myocardium. Clin Aviation Aerospace Med 1967, 38:66-69
10. Sutton GC, Tobin JR, Fox RT, Freeark RJ, Driscoll JF: Study of the pericardium and ventricular myocardium: exploratory mediastinotomy and biopsy in unexplained heart disease. JAMA 1963, 185:786-788
11. Paque RE, Gauntt CJ, Nealon TJ: Assessment of cell-mediated immunity against coxsackievirus B3-induced myocarditis in a primate model (Papio papio). Infect Immun 1981, 31:470-479
12. Henke A, Huber SA, Stelzner A, Whitton JL: The role of CD8+ T lymphocytes in coxsackie virus 63-induced myocarditis. J Virol 1995, 69:6720-6728
13. Woodruff JF, Woodruff JJ: Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease. J Immunol 1974, 113: 1726-1734
14. Hashimoto I, Tatsumi M, Nakagawa M: The role of T lymphocytes in the pathogenesis of Coxsackie virus B3 heart disease. Br J Exp Pathol 1983, 64:497-504
15. Ytterberg SR, Mahowald ML, Messner RP: T cells are required for coxsackievirus B1 induced murine polymyositis. J Rheumatol 1988, 15:475-478
16. Kishimoto C, Abelmann WH: In vivo significance of T cells in the development of Coxsackievirus B3 myocarditis in mice: immature but antigen-specific T cells aggravate cardiac injury. Circ Res 1990, 67:589-598
17. Godeny EK, Gauntt CJ: In situ immune autoradiographic identification of cells in heart tissues of mice with coxsackievirus B3-induced myocarditis. Am J Pathol 1987, 129:267-276
18. Seko Y, Shinkai Y, Kawasaki A, Yagita H, Okumura K, Takaku F, Yazaki Y: Expression of perforin in infiltrating cells in murine hearts with acute myocarditis caused by coxsackievirus B3. Circulation 1991, 84:788-795
19. Chen SX, Mei SW, Bao SH, Zheng XJ, Chang PL, Yao JS, Yao S, Zhang DQ: Immunological status and pathology of coxsackie B viral myocarditis and dilated cardiomyopathy. Chin Med J (Engl) 1993, 106:659-664
20. Seko Y, Tsuchimochi H, Nakamura T, Okumura K, Naito S, Imataka K, Fujii J, Takaku F, Yazaki Y: Expression of major histocompatibility complex class I antigen in murine ventricular myocytes infected with Coxsackievirus B3. Circ Res 1990, 67:360-367
21. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ Podack ER, Zinkernagel RM, Hengartner H: Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994, 369:31-37
22. Walsh CM, Matloubian M, Liu CC, Ueda R, Kurahara CG, Christensen JL, Huang MT, Young JD, Ahmed R, Clark WR: Immune function in mice lacking the perforin gene. Proc Natl Acad Sci USA 1994, 91: 10854-10858
23. Seko Y, Shinkai Y, Kawasaki A, Yagita H, Okumura K, Yazaki Y: Evidence of perforin-mediated cardiac myocyte injury in acute murine myocarditis caused by Coxsackie virus 83. J Pathol 1993, 170:53-58
24. Huber SA, Job LP: Cellular immune mechanisms in Coxsackievirus group B, type 3 induced myocarditis in BALB/C mice. Adv Exp Med Biol 1983, 161:491-508
25. Cook DN, Beck MA, Coffman TM, Kirby SL, Sheridan JF, Pragnell IB, Smithies O: Requirement of MIP-1α or an inflammatory response to viral infection. Science 1995, 269:1583-1585
26. Asensio VC, Campbell IL: Chemokine gene expression in the brains of mice with lymphocytic choriomeningitis. J Virol 1997, 71:7832-7840
27. Lane TE, Paoletti AD, Buchmeier MJ: Disassociation between the in vitro and in vivo effects of nitric oxide on a neurotropic murine coronavirus. J Virol 1997, 71:2202-2210
28. Reyes MP, Lerner AM: Coxsackievirus myocarditis - with special reference to acute and chronic effects. Prog Cardiovasc Dis 1985, 27:373-394
29. Martino TA, Liu P, Petric M, Sole MJ: Enteroviral myocarditis and dilated cardiomyopathy: a review of clinical and experimental studies. Human Enterovirus Infections. Edited by HA Rotbart. Washington, DC, ASM Press, 1995, pp 291-351
30. Levi G, Scalvini S, Volterrani M, Marangoni S, Arosio G, Quadri A: Coxsackie virus heart disease: 15 years after. Eur Heart J 1988, 9:1303-1307
31. Archard LC, Bowles NE, Cunningham L, Freeke CA, Olsen EG, Rose ML, Meany B, Why HJ, Richardson PJ: Molecular probes for detection of persisting enterovirus infection of human heart and their prognostic value. Eur Heart J 1991, 12(suppl D):56-59
32. Bowles NE, Rose ML, Taylor P, Banner NR, Morgan-Capner P, Cunningham L, Archard LC, Yacoub MH: End-stage dilated cardiomyopathy: persistence of enterovirus RNA in myocardium at cardiac transplantation and lack of immune response. Circulation 1989, 80:1128-1136
33. Gauntt CJ, Gomez PT, Duffey PS, Grant JA, Trent DW, Witherspoon AM, Paque RE: Characterization and myocarditic capabilities of coxsackievirus B3 variants in selected mouse strains. J Virol 1984, 52: 598-605
34. Loudon RP, Moraska AF, Huber SA, Schwimmbeck P, Schultheiss P: An attenuated variant of Coxsackievirus B3 preferentially induces immunoregulatory T cells in vivo. J Virol 1991, 65:5813-5819
35. Wolfgram LJ, Beisel KW, Herskowitz A, Rose NR: Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice. J Immunol 1986, 136:1846-1852
36. Chow LH, Gauntt CJ, McManus BM: Differential effects of myocarditic variants of Coxsackievirus B3 in inbred mice: a pathologic characterization of heart tissue damage. Lab Invest 1991, 64:55-64
37. Huber SA, Job LP, Auld KR, Woodruff JF: Sex-related differences in the rapid production of cytotoxic spleen cells active against uninfected myofibers during Coxsackievirus B-3 infection. J Immunol 1981, 126:1336-1340
38. Huber SA, Pfaeffle B: Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3. J Virol 1994, 68:5126-5132
39. Khatib R, Chason JL, Silberberg BK, Lerner AM: Age-dependent pathogenicity of group B coxsackieviruses in Swiss-Webster mice: infectivity for myocardium and pancreas. J Infect Dis 1980, 141:394-403
40. Woodruff JF, Kilbourne ED: The influence of quantitated post-weaning undernutrition on coxsackievirus B3 infection of adult mice. I. Viral persistence and increased severity of lesions. J Infect Dis 1970, 121:137-163
41. Huber SA, Job LP, Woodruff JF: In vitro culture of coxsackievirus group B, type 3 immune spleen cells on infected endothelial cells and biological activity of the cultured cells in vivo. Infect Immun 1984, 43:567-573
42. Heim A, Canu A, Kirschner P, Simon T, Mall G, Hofschneider PH, Kandolf R: Synergistic interaction of interferon-beta and interferon-gamma in coxsackievirus B3-infected carrier cultures of human myocardial fibroblasts. J Infect Dis 1992, 166:958-965
43. Kandolf R, Canu A, Hofschneider PH: Coxsackie B3 virus can replicate in cultured human foetal heart cells and is inhibited by interferon. J Mol Cell Cardiol 1985, 17:167-181
44. Herzum M, Ruppert V, Kuytz B, Jomaa H, Nakamura I, Maisch B: Coxsackievirus B3 infection leads to cell death of cardiac myocytes. J Mol Cell Cardiol 1994, 26:907-913
45. Hofschneider PH, Klingel K, Kandolf R: Toward understanding the pathogenesis of enterovirus-induced cardiomyopathy: molecular and ultrastructural approaches. J Struct Biol 1990, 104:32-37
46. Klingel K, Kandolf R: The role of enterovirus replication in the development of acute and chronic heart muscle disease in different immunocompetent mouse strains. Scand J Infect Dis Suppl 1993, 88: 79-85
47. Gomez RM, Lopez Costa JJ, Pecci Saavedra G, Berria MI: Ultrastructural study of cell injury induced by coxsackievirus B3 in pancreatic and cardiac tissues. Medicina (B Aires) 1993, 53:300-306
48. McManus BM, Chow LH, Wilson JE, Anderson DR, Gulizia JM, Gauntt CJ, Klingel KE, Beisel KW, Kandolf R: Direct myocardial injury by enterovirus: a central roe in the evolution of murine myocarditis. Clin Immunol Immunopathol 1993, 68:159-169
49. Chow LH, Beisel KW, McManus BM: Enteroviral infection of mice with severe combined immunodeficiency: evidence for direct viral pathogenesis of myocardial injury. Lab Invest 1992, 66:24-31
50. Seko Y, Yoshifumi E, Yagita H, Okumura K, Yazaki Y: Restricted usage of T-cell receptor V alpha genes in infiltrating cells in murine hearts with acute myocarditis caused by coxsackie virus B3. J Pathol 1996, 178:330-334
51. Guthrie M, Lodge PA, Huber SA: Cardiac injury in myocarditis induced by Coxsackievirus group B, type 3 in Balb/c mice is mediated by Lyt 2 + cytolytic lymphocytes. Cell Immunol 1984, 88:558-567
52. Wong CY, Woodruff JJ, Woodruff JF: Generation of cytotoxic T lymphocytes during coxsackievirus B-3 infection. II. Characterization of effector cells and demonstration of cytotoxicity against viral-infected myofibers. J Immunol 1977, 118:1165-1169
53. Wong CY, Woodruff JJ, Woodruff JF: Generation of cytotoxic T lymphocytes during coxsackievirus B-3 infection. III. Role of sex. J Immunol 1977, 119:591-597
54. Huber SA: Coxsackievirus-induced myocarditis is dependent on distinct immunopathogenic responses in different strains of mice. Lab Invest 1997, 76:691-701
55. Huber SA, Moraska A, Choate M: T cells expressing the gamma delta T-cell receptor potentiate coxsackievirus BS-induced myocarditis. J Virol 1992, 66:6541-6546
56. Huber SA, Mortensen A, Moulton G: Modulation of cytokine expression by CD4+ T cells during coxsackievirus B 3 infections of BALB/c mice initiated by cells expressing the γδ+ T-cell receptor. J Virol 1996, 70:3039-3044
57. Kagi D, Seiler P, Pavlovic J, Ledermann B, Burki K, Zinkernagel RM, Hengartner H: The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur J Immunol 1995, 25:3256-3262
58. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66:233-243
59. Rouvier E, Luciani MF, Golstein P: Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med 1993, 177:195-200
60. Suda T, Nagata S: Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 1994, 179:873-879
61. Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, Nagata S: The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992, 148:1274-1279
62. Nagata S, Suda T: Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995, 16:39-43
63. Ramsay AJ, Ruby J, Ramshaw IA: A case for cytokines as effector molecules in the resolution of virus infection. Immunol Today 1993, 14:155-157
64. Guidotti LG, Chisari FV: To kill or to cure: options in host defense against viral infection. Curr Opinion Immunol 1996, 8:478-483
65. Seko Y, Takahashi N, Yagita H, Okumura K, Yazaki Y: Expression of cytokine mRNAs in murine hearts with acute myocarditis caused by coxsackievirus B3. J Pathol 1997, 183:105-108
66. Herzum M, Huber SA, Weller R, Grebe R, Maisch B: Treatment of experimental murine Coxsackie B3 myocarditis. Eur Heart J 1991, 12(suppl D):200-202
67. Kishimoto C, Takada H, Kuroki Y, Matsushita I, Hiraoka Y, Kurokawa M, Ochiai H, Sasayama S: Enhancement of coxsackievirus B3 myocarditis in mice by lobenzarit disodium through inhibition of splenic pan T cells. Cardiovasc Res 1993, 27:243-248
68. Rezkalla S, Khatib G, Khatib R: Coxsackievirus B3 murine myocarditis: deleterious effects of nonsteroidal anti-inflammatory agents. J Lab Clin Med 1986, 107:393-395
69. Costanzo-Nordin MR, Reap EA, O'Connell JB, Robinson JA, Scanlon PJ: A nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis. J Am Coll Cardiol 1985, 6:1078-1082
70. Hiraoka Y, Kishimoto C, Kurokawa M, Ochiai H, Sasayama S: The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis. J Pharmacol Exp Ther 1992, 260:1386-1391
71. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE: A clinical trial of immunosuppressive therapy for myocarditis: The Myocarditis Treatment Trial Investigators. N Engl J Med 1995, 333:269-275